Stay updated on Pembrolizumab for Advanced Acral Lentiginous Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Advanced Acral Lentiginous Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Advanced Acral Lentiginous Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:46:20.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the Overall Response Rate (ORR) calculation for biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:05.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying inclusion and exclusion criteria, as well as general information about clinical research. Previously, no information was provided in this section.
    Difference
    49%
    Check dated 2024-05-22T21:12:51.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:44:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Advanced Acral Lentiginous Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Advanced Acral Lentiginous Melanoma Clinical Trial page.